As advised via Pharmac Tender announcement 31 August 2018 there is to be a change in the listing and future sole supply.

New listing from 1 March 2019

Nivestim Inj 300 mcg per 0.5 ml prefilled syringe 10          Pharmacode 2561956  Schedule price $96.22

Nivestim Inj 480 mcg per 0.5 ml prefilled syringe 10          Pharmacode 2561964  Schedule price $161.50

Incumbent brand

Zarzio Inj 300 mcg per 0.5 ml prefilled syringe 5                 Pharmacode 2406403   Schedule price $270.00

Zarzio Inj 480 mcg per 0.5 ml prefilled syringe 5                 Pharmacode 2406411   Schedule price $432.00       

Reference pricing will apply from 1 May 2019.

HML (Hospital Supply Status) commences 1 May 2019 and CSS (Community Supply Status) commences 1 August 2019.

As of the date of this notification ProPharma / PWR cannot accept Zarzio Injections for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically (where practical) as existing stocks are exhausted.

Benefit of staying with incumbent

Zarzio Inj 300 mcg 5 @ $270.00 x 4% = $10.80 plus per pack fee of $0.253 = Total $11.0530, compared to Nivestim @$96.22 x 3% = $1.4433 (divided by 2 for equivalent pack size) plus half of per pack fee $0.1265 = Total $1.5698

Zarzio Inj 480 mcg 5 @ $432.00 x 4% = $17.28 plus per pack fee of $0.253 = Total $17.5330, compared to Nivestim @ $161.50 x 4% = $3.2300 (divided by 2 for equivalent pack size) plus half of per pack fee $0.1265 = Total $3.3565

You simply need to manage your stock so that you have ZERO stock at time of reference pricing being 1 May 2019 unless otherwise advised.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close